To include your compound in the COVID-19 Resource Center, submit it here.

Caplyta’s unanticipated schizophrenia approval lifts Intra-Cellular shares

Emerging from a cloud of regulatory questions and mixed clinical results, Intra-Cellular has received FDA approval of Caplyta lumateperone for schizophrenia, sending the company’s shares up 193% to $36.51 on Monday.

The stock move added more than $1.3 billion to the company’s market cap.

The agency approved

Read the full 469 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers